Kontakt 2005, 7(3-4):211-218 | DOI: 10.32725/kont.2005.043

Clinical significance of therapeutic drug monitoring in pharmacotherapy rationalization and individualizationNursing

Jozef Novotný
Jihočeská univerzita v Českých Budějovicích, Zdravotně sociální fakulta, katedra ošetřovatelství

The monitoring of drug levels has not only academic significance, but it also enables pharmacotherapy rationalization and protects the patient in case of high dose therapy often in the field of toxic doses that damage vital organs (kidney, heart, hematoporesis, mucous membranes etc.).
Therapeutic Drug Monitoring (TDM) is one of the means to increase safety and efficiency of pharmacotherapy, enabling dose adaptation to the individual patient. It is based on the possibility of fixing the drug concentration in biological liquids, most often in plasma or in urine, but also in saliva etc. TDM is a part of monitoring of treatment of chronically and critically ill patients. It is substantiated in patients with different pharmakinetics of drugs - older patients, newborns, children etc.
The monitoring of drug levels during therapy, or therapeutic drug monitoring, is complex analytic activity that, unlike simple drug analytics in biologic material (intoxication etc.), studies also other factors that are important with regard to dynamics of organism during illness and therapy.
The aim of monitoring of drug levels during pharmacotherapy is:
* analysis of drugs with narrow therapeutic range;
* application at drugs with well defined relation between drug concentration and effect (either therapeutic or toxic);
* analysis of drugs with great interindividual or intraindividual differences in pharmaceutical distribution or its clearance;
* to define the right regime and program of medication dosage for individual patients, i.e. individualization of pharmacotherapy;
* to reach optimally efficient drug concentration for therapy result;
* to forestall origin of toxic manifestations, e.g. gentamycine, digoxine, cyclosporine etc.;
* to follow continuously the changes during certain pharmacotherapy and to adapt it to current patient's condition and needs;
* to follow patient's compliance during the introduced therapy.

Keywords: therapeutic drug monitoring; rational pharmacotherapy; pharmacotherapy individualization; complex analytic activity; therapeutic range of medication; compliance; polytherapy; drug interaction; patient's age; interpretation of drug levels

Published: November 22, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novotný J. Clinical significance of therapeutic drug monitoring in pharmacotherapy rationalization and individualization. Kontakt. 2005;7(3-4):211-218. doi: 10.32725/kont.2005.043.
Download citation

References

  1. Aitken, M.L. & Martin, R.R. 1987: Life-threatening theophylline toxicity is not predictable by serum level. Chest 91: 10-14. Go to original source... Go to PubMed...
  2. Aronson, J.K. & Hardman, M. 1992.: Digoxin. Brit. Med. J. 305: 1149-1152. Go to original source... Go to PubMed...
  3. Austin, M.-P.V., Souza, F.G.M. & Goodwin, G.M. 1991: Lithium augmentation in antidepressant-resistant patients: a quantitative analysis. Brit. J. Psychiatry 159: 510-514. Go to original source... Go to PubMed...
  4. Baštecký, J. et al. 1994: Gerontopsychiatrie. Praha: Grada-Avicenum, 317 pp.
  5. Beeson, P.B., McDermott, W. & Wyngaarden, J.B. 1979: Cecil TEXTBOOK OF MEDICINE. Fifhteenth Edition. W.B. Saunders Co., Philadelphia, 2356 pp.+ i CXIX.
  6. Begg, E. 2002: Instant Clinical Pharmacology. Blackwell Publishing, 120 pp.
  7. Bellibas, S.E. et al. 1994: Lithium and anticholinergics combination to maintain a stable lithium plasma level. Hum. Psychopharmacol. Clin. Exp. 9: 33-36. Go to original source...
  8. Benet, L. Z. & Galeazzi, R. L. 1979: Noncompartmental determination of the steady-state volume of distribution. J. Pharm. Sci. 68: 1071-1074. Go to original source... Go to PubMed...
  9. Benet, L. Z. 1978: Effect of route of administration and distribution on drug action. J. Pharmacokinet. Biopharm. 6: 559-585. Go to original source... Go to PubMed...
  10. Bertino, J. S., Jr. & Walker, J. W. 1987: Reassessment of theophylline toxicity. Serum concentrations, clinical course, and treatment. Arch. Intern. Med. 147: 757-760. Go to original source... Go to PubMed...
  11. Bloom, F.E. et al. 1983. Chemical and physiological aspects of the actions of lithium and antidepressant drugs. Neuropharmacology 22: 359-365. Go to original source... Go to PubMed...
  12. Boton, R., Gaviria, M. & Battle, D. C. 1987: Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am. J. Kidney Dis. 10: 329-345. Go to original source... Go to PubMed...
  13. Brackett, L. E., Shamin, M. T. & Daly, J.W. 1990: Activities of caffeine, theophylline, and enprophylline analogs as tracheal relaxants. Biochem. Pharmacol. 39: 1897-1904. Go to original source... Go to PubMed...
  14. Brody, T. M., Larner, J. & Minneman, K.P. 1998: Human Pharmacology. Molecular to Clinical. Third Edition. Mosby Year Book, St. Louis, 1001 pp.
  15. Cade, J. F. L. 1949: Lithium salts in the treatment of psychotic excitement. Med. J. Aust. 2: 349-352. Go to original source... Go to PubMed...
  16. Cassem, N. 1982: Cardiovascular effets of antidepressants. J. Clin. Psychiatry 43: 22-29.
  17. Commandeur, J. N. M. et al. 1995: Enzymes and transport systems involved in the formation and disposition of the glutathione S-conjugates: role in bioactivation and detoxification mechanisms of xenobiotics. Pharmacol. Rev. 47: 271-330. Go to PubMed...
  18. Copper, T. B. & Simpson, G. M. 1976: The 24-hour lithium level as a prognosticator of dosage requirements: a two-year follow-up study. Am. J. Psychiatry 133: 262-265. Go to original source... Go to PubMed...
  19. Cummings, M.A. et al. 1993: A prospective clinical evaluation of an equation to predict lithium dose. J. Clin. Psychiatry 54: 55-58.
  20. Depaulo, J. R., Correa, E.I. & Sapir, D.G. 1981: Renal toxicity of lithium and its implications. Johns Hopkins Med. J. 149: 15-21. Go to PubMed...
  21. DiPiro, J., T., et al. 1997: PHARMACOTHERAPY. A Pathophysiological Approach. Third Edition. Appleton & Lange, Stanford, Connecticut, 2886 pp.
  22. Drazen, J.M. et al. 1999: Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 340: 197. Go to original source... Go to PubMed...
  23. Dubovsky, S. L. 1993: Calcium antagonists in manic-depressive illness. Neuropsychobiology 29: 184-192. Go to original source... Go to PubMed...
  24. Ellsworth, A. J. et al. 2003: Mosby's 2004 Medical Drug Reference. C.V. Mosby, 1248 pp.
  25. Faedda, G. L. et al. 1993: Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar diseases. Arch. Gen. Psychiatry 50: 448-455. Go to original source... Go to PubMed...
  26. Freeman, J.M. 1992.: The best medicine for febrile seizures. N. Engl. J. Med. 327: 1161-1163. Go to original source... Go to PubMed...
  27. Füsgen, I. 1996: Der ältere Patient, Urban & Schwarzenberg, 2nd ed., Mőnchen-Wien-Baltimore, 745 pp.
  28. Goldfrank, L. et al. 2002: Goldfrank's Toxicologic Emergencies. 7th Edition. McGRAW-Hill Professional, 2170 pp.
  29. Green, G. B. et al. 2004: Washington Manual of Medical Therapeutics. 31st Edition. Lippincott Williams & Wilkins, 738 pp.
  30. Hardman, J. G. et al. 2001: Goodman & Gilman's The PHARMACOLOGICAL BASIS OF THERAPEUTICS. 10th Edition. McGRAW-Hill Professional, 1825 pp.
  31. Hook, J. B. 1992: TOXICOLOGY OF THE KIDNEY (Target Organ Toxicology Series). 2nd Edition. Lippincott Williams & Wilkins, 576 pp.
  32. Howanitz, P. J. & Steidel, S.J. 1993: Digoxin therapeutic drug monitoring practices. Arch. Pathol. Lab. Med. 117: 684-690.
  33. Choi, O. H. et al. 1988: Caffeine and theophylline analogues: correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors.. Life Sci. 43: 387-398. Go to original source... Go to PubMed...
  34. Chou, J. C.-Y. 1991: Recent advances in treatment of acute mania. J. Clin. Psychopharmacol. 11: 3-21. Go to original source... Go to PubMed...
  35. Kalvach, Z. et al. 1995: Vybrané kapitoly z geriatrie a medicíny chronických stavů, II. díl, Univerzita Karlova, Praha, 214 pp.
  36. Kasper, D. L. et al. 2004: Harrison's Principles of INTERNAL MEDICINE. 16th Edition. McGRAW-Hill Professional, 2607 pp.
  37. Katzung, B. G. & Katzung, B. 2003: Basic & Clinical Pharmacology. 9th Edition. McGraw-Hill Medical, 1088 pp.
  38. Kelly, R.A. & Smith, T.W. 1992a: Recongition and management of digitalis toxicity. Am. J. Cardiol. 69: 108G-119G. Go to original source... Go to PubMed...
  39. Kelly, R. A. & Smith, T.W. 1992b: Use and misuse of digitalis blood levels. Heart Dis. Stroke 1: 117-122. Go to PubMed...
  40. Kelly, R. A. & Smith, T. W. 1993: Digoxin in heart failure: implications of recent trial. J. Am. Coll. Cardiol. 22: 107A-112A. Go to original source... Go to PubMed...
  41. Kelly, R. A. & Smith, T.W. 1994: Endogenous cardiac glycosides. Adv. Pharmacol. 25: 263-288. Go to original source... Go to PubMed...
  42. Klaassen, C. D., Watkins, J.B. & Casarett, L.J. 2003: Casarett & Doull's Essentials of Toxicology. 1st Edition. McGraw-Hill Professional, 512 pp.
  43. Klotz, U. et al. 1975: The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J. Clin. Invest. 55: 347-359. Go to original source... Go to PubMed...
  44. Krisanda, T. J. 1992: Digitalis toxicity. Postgrad. Med. 91: 273-282. Go to original source... Go to PubMed...
  45. Lennard, M. S. 1993: Genetically determined adverse drug reactions involving metabolism. Drug Safety 9: 60-77. Go to original source... Go to PubMed...
  46. Lewis, R. P. 1992: Clinical use of serum digoxin concentrations. Am. J. Cardiol. 69: 97G-107G. Go to original source... Go to PubMed...
  47. Lindgren, S. et al. 1992: Does asthma or treatment with theophylline limit children's academic performance? N. Engl. J. Med. 327: 926-930. Go to original source... Go to PubMed...
  48. MacDonald, R. L. & Kelly, K. M. 1993: Antiepileptic drug mechanisms of action. Epilepsia 34, Suppl. 5: S1-S8. Go to original source...
  49. Mahdyoon, H. et al. 1990: The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988, Am. Heart J. 120: 1189-1194. Go to original source... Go to PubMed...
  50. McFadden, E. R., Jr. 1991: Methylxanthines in the treatment of asthma: the rise, the fall, and the possible rise again. Ann. Intern. Med. 115: 323-324. Go to original source... Go to PubMed...
  51. McPhee, S. J., Lingappa, W. R. & Ganong, W.F. 2002: Pathophysiology of Disease. 4th Edition. McGraw-Hill Medical, 760 pp.
  52. Murciano, D. et al. 1989: A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N. Engl. J. Med. 315: 800-804. Go to original source... Go to PubMed...
  53. Nasser, S. S. & Rees, P.J. 1993: Theophylline. Current thoughts on the risks and benefits of its use in asthma. Drug Safety 8: 12-18. Go to original source... Go to PubMed...
  54. Nelson, D. R. et al. 1993: The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12: 1-51. Go to original source... Go to PubMed...
  55. Novotný, J. 1997: Do we need Scientific, Technologic, Ethical and/or Humanistic Qualities of Today's Physician ? J. Health Man. Public Health, Vol. 2, No.2: 34-44.
  56. Novotný, J. 1998: Monitorovanie hladín liekov u onkologických pacientov. Folia Universitatis Tyrnaviensis, 1998, Vol. 5, No.1: 53-57.
  57. Novotný, J. 1999.: Nozokomiálne infekcie a antibiotiká. p. 47-81. In: Olejník, J. a kol.: Perioperačná starostlivosť. Bratislava: EBNER.
  58. Novotný, J. 1999: Pharmacoeconomics: principles, methods and application to pharmacotherapy. J.Health Man. and Public Health, No.4(1): 36-42.
  59. Novotný, J. 2001: Procalcitonin - an innovative diagnostic and prognostic parameter of septicaemia. J. Anästhesie u. Intensivbehandlung, Nr.2: 73.
  60. Novotný, J., 2005: Toxikológia. In: Kováč, G. et al.: Základy racionálnej klinickobiochemickej diagnostiky. Bratislava: PARTNERS, in press.
  61. Novotný, J. & Novotný, M. 1999.: Adverse drug reactions to antibiotics and major antibiotic drug interactions. Gen. Physiol. Biophys. 8: Focus Issue, 126-139.
  62. Novotný, J. & Novotný, M. 2000: Drug nephrotoxocity and its prevention. BIOLOGIA Bratislava, 55/Suppl. 8: 95-102.
  63. Novotný, J., Šramka, M. & Novotný, M. 1998: The penetration of drugs into normal and tumor tissue of the human brain. p. 113-117. In: CLINICAL NEUROPHYSIOLOGY. Ed.: Korczyn, A., D. Bologna Monduzzi Editore, Litosei-Rastignano
  64. Pacovský, V. 1994.: Geriatrie. Geriatrická diagnostika. Scientia medica, Praha, 150 pp.
  65. Paloucek, F. P. & Rodvold, K.A. 1988: Evaluation of theophylline overdoses and toxicities. Ann. Emerg. Med. 17: 135-144. Go to original source... Go to PubMed...
  66. Pickenhain, L. & Ries, W. 1988: Das Alter, Kleine Enzyklopädie, Bibliographisches Institut, Leipzig, 703 pp.
  67. Piergies, A. A., Worwag, E.M. & Atkinson, A.J. 1994: A concurrent audit of high digoxin plasma levels. Clin. Pharmacol. Ther. 55: 353-358. Go to original source... Go to PubMed...
  68. Rang, H. P. et al. 2003: PHARMACOLOGY. Churchill Livingstone, 797 pp.
  69. Rapp, D. 2003: Our Toxic World: A Wake Up Call. CAMPUSl, Inc., 511 pp.
  70. Rowe, D. J. F. et al. 1988: The clinical use and measurement of theophylline. Ann. Clin. Biochem. 25: 4-26. Go to original source... Go to PubMed...
  71. Self, T. H. et al. 1992: Reassessment of the role of theophylline in the current therapy for nocturnal asthma. J. Am. Board Fam. Pract. 5: 281-288. Go to PubMed...
  72. Schou, M. 1968: Lithium in psychiatric therapy and prophylaxis. J. Psychiatr. Res. 6: 67-95. Go to original source... Go to PubMed...
  73. Smith, T. W. 1993: Digoxin in heart failure. N. Engl. J. Med. 329: 51-53. Go to original source... Go to PubMed...
  74. Stoloff, S. W. 1994: The changing role of theophylline in pediatric asthma. Am. Fam Physician 49: 839-844. Go to PubMed...
  75. Taburet, A. M. & Schmit, B. 1994: Pharmacokinetic optimisation of asthma treatment. Clin. Pharmacokinet. 26: 396-418. Go to original source... Go to PubMed...
  76. Temkin, N. R. et al. 1990: A randomized double-blind study of phenytoin for the prevention of post-traumatic seizures. N. Engl. J. Med. 323: 497-502. Go to original source... Go to PubMed...
  77. Thomas, H. & Shepard, R. J. 2004: Catalog of Teratogenic Agents. 11th Edition. Johns Hopkins University Press, 510 pp.
  78. Thomson, A. H. & Brodie, M. J. 1992: Pharmacokinetic optimalization of anticonvulsant therapy. Clin. Pharmacokinet. 23: 216-230. Go to original source... Go to PubMed...
  79. Tierney, M. L., McPhee, S. J. & Papadakis, M.A. 2004: Current Medical Diagnosis & Treatment, 2005. 44st Edition. McGraw-Hill Medical, 1887 pp.
  80. Topinková, E. & Neuwirth, J. 1995: Geriatrie pro praktického lékaře, Grada-Avicenum, Praha, 300 pp.
  81. Uretsky, B. F. et al. 1993: Randomized study assessing the effect of digoxin withdrawal in patients with mild and moderate chronic congestive heart failure: resuls of the PROVED trial. J. Am. Coll. Cardiol. 22: 955-962. Go to original source... Go to PubMed...
  82. Vajda, F. J. E. 1992: New anticonvulsants. Curr. Opinion Neurol. Neurosurg. 5: 519-525.
  83. Velasco, M. et al. 1998: New Advances In Cardiovascular Physiology And Pharmacology. Excerpta Medica, 258 pp.
  84. Walsh, Ch. 2003: Antibiotics: Actions, Origins, Resistance. American Society for Microbiology, U.S.A., 335 pp. Go to original source...
  85. Wrighton, S. A. & Stevens, J. C. 1992: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22: 1-21. Go to original source... Go to PubMed...
  86. Yang, K. & Graf, L. 2003: Blueprints Pharmacology. Blackwell Publishing, 208 pp.